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❚ Evidence summary
The prevalence of migraine headache is
6% among men and 15% to 17% among
women.1 However, no standardized
approach exists for the treatment of acute
migraine headache. Systematic reviews of
randomized controlled trials (RCTs) sum-
marized that oral sumatriptan (Imitrex),
Medications collectively referred to as 
“triptans” (eg, sumatriptan, naratriptan, etc)
have been shown to be effective for acute
migraine (strength of recommendation
[SOR]: A). Nonsteroidal anti-inflammatory
drugs (NSAIDs)—including aspirin,
ibuprofen, naproxen sodium, diclofenac
potassium, ketoprofen, tolfenamic acid, and
ketorolac—are also effective (SOR: A). The
combination of acetaminophen/aspirin/
caffeine is effective (SOR: B). Parenteral
dihydroergotamine (DHE), when 
administered with an antiemetic, is as 
effective as, or more effective than 
meperidine, valproate, or ketorolac (SOR:
B). Prochlorperazine is more effective than
metoclopramide in headache pain reduction
(SOR: A). Isometheptene mucate/dichloral-
phenazone/acetaminophen is as effective
as low-dose oral sumatriptan (SOR: B).
Inadequate response to medication?
Increase dose or change route
For mild to moderate migraine headache
attacks, NSAIDs or products containing
acetaminophen and/or aspirin with caffeine
or isometheptene mucate/dichloral-
phenazone/acetaminophen, when used
intermittently, are frequently effective. More
severe attacks generally respond better to
migraine-specific medications such as 
triptans and ergot derivatives—the latter 
may be less likely to cause secondary
rebound (analgesic overuse) headaches.
Inadequate response to migraine-specific
medication should prompt the prescriber to
increase dose or change route to insure
absorption (ie, nasal, rectal, or injectable).
Emerging evidence suggests combining a
triptan plus an NSAID may produce higher
response rates and more durable 
responses. Narcotics should generally be
avoided. Valproate, ketorolac, IV magnesium,
prochlorperazine, and metoclopramide are
all somewhat effective for acute migraine,
the latter 2 agents having the advantage of
helping nausea but with the disadvantage 
of causing extrapyramidal reactions. A short
course of oral steroids may break persistent
attacks. Patients with frequent and intense
headache patterns should be offered 
prophylactic therapy and not just abortive
treatments.
Robert Sheeler, MD
Mayo Clinic, Rochester, Minn
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More severe
attacks generally
respond better to
migraine-specific
medications such
as triptans and
ergot derivatives
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eletriptan (Relpax), and rizatriptan
(Maxalt) reduced migraine headache pain
and increased the pain-free response rate
for adults when compared with placebo.2–4
The number needed to treat (NNT) ranged
from 3.9 to 9.9 for a given triptan’s lower
dose to 2.6 to 5.1 for the higher dose.2–4
RCTs reported superior efficacy of oral
almotriptan (Axert), frovatriptan (Frova),
and zolmitriptan (Zomig), as well as
intranasal sumatriptan and zolmitriptan
when compared with placebo.
The following NSAIDs reduced
headache severity more than placebo 
2 hours after treatment: aspirin (1000 mg;
NNT=2.4), ibuprofen (1200 mg; NNT=
1.8), naproxen (750 mg; NNT=2.0), 
tolfenamic acid (not available in the US;
NNT=1.2), and the combination product
of acetaminophen/aspirin/caffeine (Excedrin
Migraine, et al) (NNT=1.7).5 Aceta-
minophen 1000 mg orally has been report-
ed to be superior to placebo for treating
pain, functional disability, and photo/
phonophobia among patients who did not
require bedrest with their headaches and
did not vomit more than 20% of the time.
However, it was not superior to placebo
when given intravenously for more severe
acute migraine. No placebo-controlled tri-
als exist for the use of ketorolac (Toradol);
there are only comparison studies against
other active migraine medications.
Ketoprofen (Orudis) has placebo-con-
trolled RCT data supporting its efficacy.
A meta-analysis6 of RCTs of parenter-
al metoclopramide (Reglan) revealed sig-
nificant pain reduction (odds ratio [OR]=
2.84; 95% confidence interval [CI],
1.05–7.68). When compared with other
antiemetics (chlorpromazine [Thorazine]
and prochlorperazine [Compazine]), meto-
clopramide was either less effective
(OR=0.39; 95% CI, 0.18–0.87) or no dif-
ferent (OR=0.64; 95% CI, 0.23–1.76)
than other therapies for reducing migraine
pain. No difference was noted between
parenteral metoclopramide and subcuta-
neous sumatriptan (OR=2.27; 95% CI,
0.64–8.11); however, metoclopramide was
more effective than ibuprofen in pain
reduction scores (standard deviation data
missing in this study). 
A systematic review7 revealed that
dihydroergotamine (DHE) alone was less
effective than subcutaneous sumatriptan in
migraine pain reduction (OR=0.44; 95%
CI, 0.25–0.77) or headache resolution
(OR=0.05; 95% CI, 0.01–0.42). No differ-
ences were seen between DHE alone and
chlorpromazine or lidocaine. Three studies
revealed DHE plus metoclopramide was
more effective than or equal to other
agents for headache pain reduction at 2
hours: one vs ketorolac IM (OR=7; 95%
CI, 0.86–56.89), one vs meperidine
(Demerol) plus hydroxyzine (Vistaril,
Atarax) IM (OR=47.67; 95% CI,
4.32–526.17), and one vs valproate 
IV (OR=0.67; 95% CI, 0.19–2.33).7
Specifically, treatment with DHE plus
metoclopramide was superior to ketorolac
for pain reduction (P=.03), but patients did
not differ in disability scores (P=.06). DHE
plus metoclopramide achieved greater
reductions in pain scale scores than
meperidine plus hydroxyzine (P<.001). No
significant difference in pain reduction was
noted between DHE plus metoclopramide
and valproate (P=.36).
A multicenter, double-blind, random-
ized parallel group study8 showed no dif-
ference between the combination product
isometheptene mucate, dichloralphena-
zone with acetaminophen (Midrin,
Duradrin, etc) (used as recommended in
the package insert with a maximum of up
to 5 tablets within 24 hours) vs oral suma-
triptan (initial dose of 25 mg with a repeat
25 mg dose in 2 hours). No placebo arm
was used in this study. 
Recommendations from others
The Institute for Clinical Systems
Improvement recommends the use of
vasoactive drugs over narcotics and barbi-
turates for treatment of moderately severe
migraine headaches.9 The American
Academy of Neurology recommends
migraine-specific medications (triptans,
DHE) for moderate to severe migraines or
those mild to moderate migraines that
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responded poorly to NSAIDs or other
over-the-counter preparations.10
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